keine Finanzberatung

ABT · Abbott Laboratories

Diversified med-tech: devices, diagnostics, nutrition, branded generics

Risiko 3/10 · LOW-MODERATE RISK · diversified med-tech compounder · $108.33 ▼ 0.42%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $108.33
  • Market cap $187.5B
  • P/E (ttm) 35.06
  • Div yield 2.33%
  • 52-wk range $81.97 – $137.49
  • Index rank #73 / —

Wichtigste Risiken

  • Infant-formula litigation verdicts snowball (Shareholders) — MED
  • CGM competition erodes the Libre growth engine (Shareholders) — LOW
  • Emerging-market FX drags on established pharma (Shareholders) — LOW
  • Device pricing and regulatory squeeze on margins (Shareholders) — LOW

Fazit

A steady compounder for conservative portfolios; litigation is the main thing that could dent an otherwise low-drama story.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.